In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review

Akiko Yamashita, Nobuhiro Hidaka, Ryo Yamamoto, Soichiro Nakayama, Jun Sasahara, Keisuke Ishii, Nobuaki Mitsuda

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops.

Original languageEnglish
Pages (from-to)451-457
Number of pages7
JournalJournal of Clinical Ultrasound
Volume43
Issue number7
DOIs
Publication statusPublished - Sep 2015

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review'. Together they form a unique fingerprint.

Cite this